Stifel Downgrades OncoGenex Pharmaceuticals (OGXI) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq climb as soft inflation dampens Fed rate hike expectations
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 flat as higher bond yields counter tech optimism
OncoGenex Pharma (OGXI) to Resume Trading at 4:30 PM ET
December 1, 2015 4:11 PM ESTOncoGenex Pharma (NASDAQ: OGXI) to Resume Trading at 4:30 PM ET
... MoreOncoGenex Pharma's (OGXI) Phase 3 AFFINITY Trial with Custirsen to Continue Following Interim Analyses
December 1, 2015 4:03 PM ESTFollowing an independent Data Monitoring Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that its Phase 3 AFFINITY trial is continuing based on the pre-planned interim futility analysis of the intent-to-treat (ITT) population. In the final safety review, no new safety issues were identified by the DMC. Both the DMC and OncoGenex remain blinded to all analyses and final results are expected in the second half of 2016, depending on timing of the event-driven final analysis.
AFFINITY is designed to evaluate whether the investigational treatment custirsen, when combined with cabazitaxel, improves survival in men with... More
OncoGenex Pharma (OGXI) halted with news pending
December 1, 2015 4:00 PM ESTOncoGenex Pharma (NASDAQ: OGXI) halted with news pending.
... More